Share this post:

Anne Gulland of The BMJ covers some of the steps that companies are taking to combat AMR but states that there is much more that can be done.

“This was the Access to Medicine Foundation’s first review of company activities on antimicrobial resistance, prompted by an increased global focus. It was also the the first time that the foundation had looked in depth at generic manufacturers, which produce most of the generics developed globally.”

Read full article